Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS

Genitourinary Cancer

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Cancer Treat Rev

Zhang Y, Chen J, Liu H, Dai J, Zhao J, Zhu S, Zhang X, Liang J, Hu X, Zhao J, Liu Z, Shen P, Sun G, Zeng H

doi: 10.1016/j.ctrv.2024.102787

Further Publications

A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions

Clin Cancer Res

Küçükosmanoglu A, Scoarta S, Houweling M, Spinu N, Wijnands T, Geerdink N, Meskers C, Kanev GK, Kiewiet B, Kouwenhoven M, Noske D, Wurdinger T, Pouwer M, Wolff M, Westerman BA

doi: 10.1158/1078-0432.CCR-23-0914

Further Publications

The burden of cardiovascular disease and risk for subsequent major adverse cardiovascular events in survivors of childhood cancer: a prospective, longitudinal analysis from the St Jude Lifetime Cohort Study

Lancet Oncol

Hammoud RA, Liu Q, Dixon SB, Onerup A, Mulrooney DA, Huang IC, Jefferies JL, Rhea IB, Ness KK, Ehrhardt MJ, Hudson MM, Ky B, Bhakta N, Sapkota Y, Yasui Y, Armstrong GT

doi: 10.1016/S1470-2045(24)00157-8

Further Publications

Association between CDK4/6 inhibitors and drug-related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System

Int J Cancer

Go M, Noguchi Y, Masuda R, Asano H, Kimura M, Usami E, Yoshimura T

doi: 10.1002/ijc.34962

Further Publications

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors

Eur J Cancer

Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, Ertl C, Tomsitz D, Tietze JK, Gutzmer R, Dabrowski E, Zimmer L, Gesierich A, Zierold S, French LE, Eigentler T, Amaral T, Heinzerling L

doi: 10.1016/j.ejca.2024.114028

Skin Cancer

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome

Eur J Cancer

Jurlander RS, Guldbrandt LM, Holmstroem RB, Madsen K, Donia M, Haslund CA, Schmidt H, Bastholt L, Ruhlmann CH, Svane IM, Ellebaek E

doi: 10.1016/j.ejca.2024.115053

Lung, Respiratory and Thoracic Cancer

Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal

Lung Cancer

Chour A, Basse C, Lebossé F, Bonte PE, Girard N, Duruisseaux M

doi: 10.1016/j.lungcan.2024.107789

Further Publications

Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)

Eur J Cancer

Maglietta G, Damato A, Finotto S, Mandarà M, Tamberi S, Grisanti S, Brighenti M, Tiseo M, Montesarchio V, Catino A, Gelsomino F, Giovanardi F, Antonuzzo L, Romagnani A, Gervasi E, Di Maio M, Pinto C

doi: 10.1016/j.ejca.2025.115296

Lung, Respiratory and Thoracic Cancer

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

Oncologist

Skoulidis F, Li BT, Hochmair M, Govindan R, Vincent M, van der Wekken AJ, Reguart Aransay N, O'Byrne KJ, Girard N, Griesinger F, Nishio M, Häfliger S, Lindsay C, Reinmuth N, Paulus A, Papakotoulas P, Kim SW, Ferreira CG, Pasello G, Duruisseaux M, Gennatas S, Dimou A, Mehta B, Kormany W, Nduka C, Sylvester BE, Ardito-Abraham C, Wang Y, de Langen AJ

doi: 10.1093/oncolo/oyae356

Related content

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions

The burden of cardiovascular disease and risk for subsequent major adverse cardiovascular events in survivors of childhood cancer: a prospective, longitudinal analysis from the St Jude Lifetime Cohort Study

Association between CDK4/6 inhibitors and drug-related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome

Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal

Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer